GALAHAD: what clinicians are saying
niraparib in metastatic castration-resistant prostate cancer with DNA-repair gene defects · NCT02854436 ↗ · Phase 2 · Janssen Research & Development, LLC
Speakers interpret GALAHAD as supporting BRCA1/2-based selection because responses were less frequent with other alterations, with an explicit caution in discussion against inferring a survival improvement. Niraparib’s relative benefit drew tentative doubt in one discussion, whereas another speaker found no benefit-based reason to favor one PARP inhibitor over another. A medical oncologist requested comparative evidence; small groups with rarer alterations also leave their potential benefit uncertain.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 272 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. GALAHAD by gene: what a speaker highlights in BRCA benefit and non-BRCA uncertainty
1 of the report's 12 cited clinicians · 20 statements from 3 speakers in 8 sources, 5 of them podcasts or videos · 17 passages
Limitations recorded: 3.
Draws on: Population and setting, Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation, Design and conduct, The comparison, Secondary endpoints.
02. PARP inhibitors: where speakers split on whether efficacy can be ranked
3 of the report's 12 cited clinicians · 20 statements from 5 speakers in 10 sources, 7 of them podcasts or videos · 21 passages
Limitations recorded: 4.
Draws on: The comparison, Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation.
03. Niraparib toxicity: a speaker describes it as class-consistent and highlights anemia
No named clinician · accounts and unnamed speakers · 7 statements in 2 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 3.
Draws on: Safety and tolerability.
Beyond the trial population
04. HRR testing: most speakers prioritize it; some see assay and prediction gaps
8 of the report's 12 cited clinicians · 72 statements from 12 speakers in 10 sources, 5 of them podcasts or videos · 49 passages
Limitations recorded: 4.
05. PARP safety: how speakers weigh symptom control against long-term concerns
5 of the report's 12 cited clinicians · 35 statements from 8 speakers in 5 sources, all podcasts or videos · 31 passages
Limitations recorded: 4.
06. Carboplatin: some speakers consider it if PARP access fails but lack head-to-head data
3 of the report's 12 cited clinicians · 16 statements from 5 speakers in 4 sources, 3 of them podcasts or videos · 13 passages
Limitations recorded: 3.
07. 1L mCRPC PARP combos: how speakers weigh biomarkers, prior therapy and access
5 of the report's 12 cited clinicians · 42 statements from 6 speakers in 5 sources, 4 of them podcasts or videos · 30 passages
Limitations recorded: 4.
08. PARP failure: what speakers say
3 of the report's 12 cited clinicians · 11 statements from 3 speakers in 3 sources, 2 of them podcasts or videos · 10 passages
Limitations recorded: 3.
09. BRCA-mutated, MSI-high prostate cancer: what speakers say
3 of the report's 12 cited clinicians · 9 statements from 3 speakers in 1 source, a podcast or video · 4 passages
Limitations recorded: 4.
10. Molecularly informed prostate cancer care: most speakers support genetic counseling
2 of the report's 12 cited clinicians · 23 statements from 5 speakers in 5 sources, 4 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
1 of the report's 12 cited clinicians
GALAHAD by gene: what a speaker highlights in BRCA benefit and non-BRCA uncertainty
20 statements from 3 speakers in 8 sources, 5 of them podcasts or videos
1 of the 3 named speakers in this finding holds this view
- 20
- statements
- 17
- passages
- 8
- sources
- 3
- speakers
What the statements areViews 8Questions and uncertainty 2Clinical experience 1Comparisons 3Restated results and context 6Statement-to-passage links (a passage can back several statements)Supporting a statement 23Giving context 6Recorded with the findingLimitations: 3
2 posts and articles · 5 podcasts and video · 1 publication
Draws on: Population and setting, Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation, Design and conduct, The comparison, Secondary endpoints.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
7 of the 10 findings and 201 of the 272 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Medical oncologist · ex-US
Podcast · Jun 2025
Staff page checked · finding 2
A medical oncologist includes GALAHAD among the PARP-inhibitor monotherapy studies that provided the basis for current single-agent indications in prostate cancer.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations (6)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; MSI, microsatellite instability; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; PARP, poly(ADP-ribose) polymerase.
The full GALAHAD report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians still need to see on gene-specific responses to define niraparib monotherapy’s role beyond BRCA1/2 alterations in metastatic castration-resistant prostate cancer after androgen-signaling inhibitors and taxanes, particularly for ATM, CDK12 and rarer DNA-repair alterations?
From finding F1 (20 statements from 3 speakers in 8 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 66commentary sources screened
- 18sources cited by verified statements
- 21named in screened sources
- 20speakers cited in the report
- 16cited speakers with a verified identity
12 cited clinicians, speakers with a confirmed clinical role, of them 11 physicians. By role and specialty:
- 8 physician, Medical oncology
- 2 physician, specialty not confirmed
- 1 nurse practitioner
- 1 physician, Urology
- 272verified statements, each linked to its source
- 95of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 272 | Paid |
| Who said each statement: the cited speakers | 20 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 12 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 16 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 18 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
14 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation | 6 | 4 |
| Secondary endpoints | 2 | 1 |
| Population and setting | 11 | 6 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 12 | 7 |
| Safety and tolerability | 5 | 5 |
| Design and conduct | 5 | 3 |
| Molecular selection, alteration type and testing access | 67 | 9 |
| Agent differentiation and time-specific regulatory context | 18 | 9 |
| Class safety, individualized management and delayed harms | 35 | 5 |
| Platinum alternatives, affordability and comparative evidence | 16 | 4 |
| Earlier combination choices and reasons to defer broader use | 41 | 4 |
| Response waiting, progression and subsequent treatment | 9 | 2 |
| Coexisting BRCA and MSI findings as an alternative-treatment question | 9 | 1 |
| Patient understanding, nursing support and genetic counseling | 23 | 5 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
272 verified statements from 18 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 220 statements · 81% | ||||
| YouTube | 51 | 2 | 2 | |
| X videos | 0 | 0 | 1 | |
| Podcasts | 169 | 5 | 5 | |
| Posts · 17 statements · 6% | ||||
| X threads | 17 | 8 | 56 | |
| LinkedIn posts | 0 | 0 | 1 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 35 statements · 13%cited for context, not screened | ||||
| Publications | 33 | 2 | — | |
| Registry | 2 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 14 / quarter
- Screened window
- Feb 8, 2018 → Oct 4, 2026
- Cited window
- Sep 18, 2018 → Jun 16, 2025
- Retrieved
- Nov 18, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
- Registry
- NCT02854436
- Study IDs
- CR108208 · 64091742PCR2001 (Janssen Research & Development, LLC) · 2016-002057-38
- Sponsor
- Janssen Research & Development, LLC
- Design
- Phase 2 · Interventional, single group
- Status
- Completed
- Enrollment
- 289 actual
- Registered
- 2016-08-03
- Start
- 2016-08-31 actual
- Primary completion
- 2021-01-26 actual
- Primary endpoint
- Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation
- Interventions
- 1 registered
More on: Prostate cancer, niraparib
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on assessment methods, mutation-defined benefit and survival uncertainty with PARP inhibition in metastatic castration-resistant prostate cancer; a view on biomarker selection and comparator choices for PARP-inhibitor treatment in DNA-repair–altered metastatic castration-resistant prostate cancer; a view on genetic testing, patient selection and evidence beyond scans when weighing PARP inhibition; a view on PARP inhibitor efficacy in BRCA-mutated metastatic castration-resistant prostate cancer; a view on having to defer treatment until castration resistance if approval is restricted to that setting; a view on assessment methods and mutation-specific evidence informing treatment selection in metastatic castration-resistant prostate cancer; a view on biomarker-guided selection and reasons to withhold PARP inhibition in metastatic castration-resistant prostate cancer; a view on how BRCA and other DNA-repair alterations qualify interpretation of progression and survival evidence; a view on interpreting PARP-inhibitor survival evidence in DNA-repair-altered metastatic castration-resistant prostate cancer when crossover occurs; a view on microsatellite instability work-up and immunotherapy selection in BRCA-mutated prostate cancer; a view on distinguishing pulmonary-only from liver metastases when assessing prognosis in metastatic castration-resistant prostate cancer.
- 2 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 259 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 18 known gaps +Fewer −
- Further source limits: 18 sources about other trials or topics are not included.
- ClinicalTrials.gov first posted results for the trial on 8 March 2022.
- The sources reviewed include historical remarks from 2018 through June 2025. Approval, reimbursement, enrollment and anticipated-study statements retain their discussion timing and do not describe current universal availability.
- This is a qualitative selection of public discussion, not a representative survey. A source count, repeated panel remarks, reposts or language versions cannot be treated as an independent-HCP count or a consensus measure.
- Some passages do not identify their speakers sufficiently for named attribution. Their views remain attributed to their episodes or discussions rather than assigned from a program roster or neighboring remarks.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Discussions without the trial name or using other wording may be absent. The material reviewed therefore cannot establish the complete public conversation about GALAHAD's clinical question.
- Some relevant portions of the April 2023 episode remain incompletely assessed, including discussion of patient benefit beyond scans, testing, approval and treatment timing. Their absence may affect the balance of practical and patient-centered views.
- Treatment-choice coverage is incomplete: the October 2022 webinar's concluding monotherapy-sequencing assessment and its treatment-history rationale are not fully represented, nor is a speaker's explanation of regional monotherapy approvals. This limits conclusions about preferred sequencing and the evidentiary reasons behind European and US differences.
- The dose-reduction discussion captures a speaker's case-derived generalization, not a detailed patient-level toxicity course. It cannot quantify how often dose adjustment restores tolerability.
- The full text of the separate GALAHAD quality-of-life publication was unavailable. Its abstract supports publication context but not a complete appraisal of that analysis or clinician uptake.
- GALAHAD's nonrandomized cohort comparisons do not establish superiority over another treatment or a causal survival advantage. Cross-trial agent rankings and combination-dose explanations remain attributed, qualified opinions.
- A talk described GALAHAD as involving roughly 50 patients; that is the speaker's approximate description, not the final study enrollment reported in the publication.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. GALAHAD (NCT02854436): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/galahad-nct02854436
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "GALAHAD" (NCT02854436), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "galahad-nct02854436". If you cannot make requests, read https://www.erudio.com/reports/galahad-nct02854436.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT02854436", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT02854436 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/galahad-nct02854436.json
curl https://www.erudio.com/reports/galahad-nct02854436.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "galahad-nct02854436" })release bb34f6aa728d2d4fd7240e480cee246d8c587720b781854a429bc49b32a1708f
Questions
How much does the GALAHAD report cost?
One edition costs $1,250 (Standard · 272 verified statements · 95 from 12 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the GALAHAD report cover?
272 statements from 18 sources (5 podcasts, 2 videos, 8 posts, 2 papers, 1 registry record), 95 of them from 12 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the GALAHAD report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "galahad-nct02854436" }) previews it and create_order({ "report": "galahad-nct02854436", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the GALAHAD report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.